Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its ...

CVS Health (NYSE:CVS) on Thursday announced plans to discontinue operations in the individual health insurance business, also ...

The FTSE 100 ended Wednesday 0.37% higher, continuing its longest winning run since late 2016 into early 2017.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

Eli Lilly (LLY) stock dips as CVS Health (CVS) limits access to its weight loss drug Zepbound in favor of Novo Nordisk's (NVO ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), ...

Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.

Shares of Novo Nordisk surged after the Danish drugmaker struck an agreement with CVS Health that will let its pharmacy-benefit manager, CVS Caremark, favor the company's weight-loss medication Wegovy ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare performance.